EE269 Cost-Effectiveness of Profile Omission of Local Adjuvant Radiotherapy (POLAR), A Novel Genomic Signature, after Breast Conserving Surgery for Women with Invasive Early-Stage Breast Cancer (ESBC)

Adjuvant radiotherapy (RT), the standard of care for women diagnosed with invasive ESBC after breast-conserving surgery (BCS), is shown to reduce the risk of recurrence for most women; however, it can be associated with major adverse effects including lung/cardiac/breast toxicity. Recently, the POLAR signature was reported to successfully identify women who would or would not benefit from RT after BCS. This study evaluated the cost-effectiveness of the POLAR signature for guiding RT omission compared to RT for all women with hormone receptor-positive (HR+), HER2-negative stage I/IIA breast cancer.